Serodus ASA Stock

Stocks

03/01/17	Serodus : Primary endpoint reached by SER150 Phase 2a study in Diabetic Nephropathy.	PU
08/12/16	Serodus : Q&A delisting from Oslo Axess	PU
23/11/16	Serodus : Extraordinary general meeting held	PU
23/11/16	Serodus : Viggo Harboe Holding 2006 ApS announces results of voluntary offer	PU
02/11/16	Serodus : Viggo Harboe Holding 2006 Aps Launces voluntary offer for outstanding shares in Serodus ASA – Acceptance period starting 31 October 2016	PU

1 day

-5.56%

Manager	Title	Age	Since
Arnstein Gunnestad Endresen CEO	Chief Executive Officer	73	01/01/2023
Henrik Mordhorst DFI	Director of Finance/CFO	-	01/10/2019
Daniel Capion PRN	Corporate Officer/Principal	-	01/01/2021

Director	Title	Age	Since
Søren Elmann Ingerslev CHM	Chairman	-	01/01/2017
Terri Sebree BRD	Director/Board Member	68	01/04/2014
Viggo Gunnersen Harboe BRD	Director/Board Member	80	01/01/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SERODUS ASA	-5.56%	+7.94%	-	-	0
WUXI APPTEC CO., LTD.	+2.35%	+0.77%	+29.92%	+85.38%	55.23B
ARGENX SE	-0.21%	-6.52%	+42.39%	+64.10%	53.75B
BIONTECH SE	-2.44%	-1.61%	-17.69%	-15.68%	23.48B
INSMED INCORPORATED	-2.85%	-8.20%	-6.26%	+361.83%	22B
WUXI BIOLOGICS (CAYMAN) INC.	+2.49%	-1.27%	+15.99%	-10.53%	19.78B
GENMAB A/S	+0.79%	-2.39%	+26.99%	-31.34%	17.44B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.58%	-7.23%	+24.50%	+519.07%	14.66B
EXELIXIS, INC.	-5.25%	-4.71%	+43.89%	+167.15%	14.07B
PHARMAESSENTIA CORPORATION	+3.41%	-7.83%	+161.76%	+284.91%	13.02B
Average	-0.67%	-1.43%	+35.72%	+158.32%	25.94B
Weighted average by Cap.	+0.17%	+0.09%	+31.05%	+122.81%

Employees

Sector